Brief: Karuna Therapeutics Reports Fourth Quarter 2022 Financial Result

Karuna Therapeutics

23/02/2023 11:44

Feb 23 (Reuters) - Karuna Therapeutics Inc  KRTX.O :
    * KARUNA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2022
FINANCIAL RESULT AND PROVIDES GENERAL BUSINESS UPDATES
    * ON TRACK TO SUBMIT NDA FOR KARXT IN SCHIZOPHRENIA TO U.S.
FDA IN
MID-2023
    * ANTICIPATES THAT TOTAL OPERATING EXPENSES WILL BE
$430-$470
MILLION FOR FULL YEAR 2023
    * TOPLINE DATA FROM PHASE 3 EMERGENT-3 TRIAL ANTICIPATED IN
Q1 OF
2023
    * $1.1 BILLION IN CASH IS EXPECTED TO FUND OPERATIONS
THROUGH END
OF 2025
    * QTRLY LOSS PER SHARE $2.22
    * TOPLINE DATA FROM PHASE 3 ADEPT-1 & ADEPT-2 TRIALS ARE
ANTICIPATED IN 2025
    * COMPANY IS ON TRACK TO INITIATE PHASE 3 ADEPT-2 TRIAL IN
SECOND
HALF OF 2023
    * Q4 EARNINGS PER SHARE VIEW $-2.25, REVENUE VIEW $5880.00
--
REFINITIV IBES DATA

Source text for Eikon:  ID:nBw8pQSKZa 
Further company coverage:  KRTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))